Zenith Endovascular Graft Continues To Show Durability

Main Category: Cardiovascular / Cardiology
Also Included In: Clinical Trials / Drug Trials
Article Date: 02 Jul 2008 - 4:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

A multicenter trial with up to five years of follow-up continues to support the mid- and long-term durability and safety of the Zenith endovascular graft used for aneurysm repair.

"Our study showed that the risk of aneurysm-related death or rupture were exceptionally low, and complications of migration, limb occlusion and device integrity issues were uncommon," said Roy Greenberg, MD, director of endovascular research at The Cleveland Clinic Foundation. Between 2000 and 2003, a total of 739 endovascular patients were enrolled in open surgery. Three hundred and fifty-two of these patients were in the pivotal (control) group and 287 were in the endovascular continued access) group where the Zenith endovascular graft was implemented. Both studies were designed for two-year follow up; however 158 patients in the pivotal study re-consented to be followed for five years.

All endovascular patients were divided into both physiologic high-risk (HR) and standard-risk (SR) groups to assess overall mortality, rupture, conversion, endoleaks, secondary interventions and sac enlargement. The entire endovascular cohort was assessed for device integrity (determined by holes in the fabric, separation/fracture of barbs and fractures of z-stents), limb occlusion, component separation and migration. A suboptimal endovascular endpoint (SER) was established to assess the risk of late adverse outcomes.

For the patients at HR and SR at five years, the respective percentages included survival estimate was 83 percent and 61 percent; aneurysm-related death was 2 percent and 4 percent; and freedom from rupture was 100 percent and 99.6 percent. Cumulative risk of conversion, limb occlusion, migration more than 10 millimeters, or component separation was 3 percent or less for all patient groups. Endoleak represented the most common indication for a secondary intervention, and the cumulative risk of late endoleak was 12 to15 percent. Secondary interventions were performed in 20 percent of standard risk patients and 25 percent of high risk patients followed through five years.

"This study, detailed in the July issue of the Journal of Vascular Surgery, found the long-term durability of the Zenith endovascular graft superior for patients amenable to open surgical repair as well as those considered to be at high physiological risk," said Dr. Greenberg. "The lack of late ruptures, the small number of conversions and low risk of migration, limb thrombosis, component separation and stent fracture relate to the quality of implant construct and patient selection."

Dr. Greenberg noted that in the study sac enlargement was very uncommon. Of the 31 patients who experienced sac enlargement, 25 were related to early or late endoleaks (80 percent of which were type II in nature), and definitive explanations for cause of sac enlargement was present for all but three patients. Predictors for sac size enlargement included advanced patient age and larger initial aneurysm size.

"Although we fully support the use of the Zenith endovascular graft, sac behavior and late endoleak incidence underscore the need of further investigation for long-term follow-up of patients treated with an endovascular graft," said Dr. Greenberg.

Competition of interest: Dr. Greenberg has received grant and research support, consulting fees and licensed intellectual property to Cook Inc.

About Journal of Vascular Surgery

Journal of Vascular Surgery provides vascular, cardiothoracic and general surgeons with the most recent information in vascular surgery. Original, peer-reviewed articles cover clinical and experimental studies, noninvasive diagnostic techniques, processes and vascular substitutes, microvascular surgical techniques, angiography and endovascular management. Special issues publish papers presented at the annual meeting of the Journal's sponsoring society, the Society for Vascular Surgery. Visit the Journal web site at http://www.jvascsurg.org.

About the Society for Vascular Surgery

The Society for Vascular Surgery (SVS) is a not-for-profit society that seeks to advance excellence and innovation in vascular health through education, advocacy, research and public awareness. SVS is the national advocate for 2,600 vascular surgeons dedicated to the prevention and cure of vascular disease. Visit the web site at http://www.VascularWeb.org.

Society for Vascular Surgery
633 N. St. Clair, 24th Fl.
Chicago, IL 60611
United States
http://www.VascularWeb.org